Format

Send to

Choose Destination
Am J Surg. 2010 Nov;200(5):577-80. doi: 10.1016/j.amjsurg.2010.07.022.

Pterostilbene and tamoxifen show an additive effect against breast cancer in vitro.

Author information

1
The University of Vermont/Fletcher Allen Health Care, Burlington, USA. patrick.mannal@vtmednet.org

Abstract

BACKGROUND:

Tamoxifen is widely used for the treatment of breast cancer. Pterostilbene, a bioavailable stilbenoid found in blueberries, has been found to inhibit breast cancer growth in vitro. It was hypothesized that combining pterostilbene with tamoxifen would produce additive effects on estrogen receptor-positive breast cancer cells.

METHODS:

Two estrogen receptor-positive breast cancer cell lines, MCF7 and ZR-751, were pretreated with graduated doses of pterostilbene for 24 hours, followed by 5 μmol/L tamoxifen. MTT proliferation assays and Cell Death Detection ELISA(PLUS) tests evaluated cell viability and apoptosis.

RESULTS:

MCF7 cells showed inhibition (10 and 20 μmol/L, P < .001; 30 μmol/L, P < .05) at all time points when combined with tamoxifen. ZR-751 cells showed additive reductions in cell viability (P < .001). Cell Death Detection ELISA(PLUS) indicated increased apoptosis (P < .01).

CONCLUSIONS:

Pterostilbene shows an additive inhibitory effect on breast cancer cells when combined with tamoxifen, most likely from augmented cancer cell apoptosis.

PMID:
21056131
DOI:
10.1016/j.amjsurg.2010.07.022
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center